Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo talk
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Phase III trials: definition
- Phase III trials are difficult
- Adjuvant chemotherapy for NSCLC
- Chemotherapy / radiation vs. radiation
- Chemotherapy vs. observation
- Statistical aspects of phase III studies: planning
- Eligibility and treatment plan
- Overall survival in total randomized population
- Statistical aspects of phase III trials: execution
- Statistical aspects of phase III trials: analysis
- Why phase III trials? (1)
- Example of phase II vs. phase III study results
- SWOG 0023 study
- S0023: overall survival
- Why phase III trials? (2)
- Bevacizumab - ECOG 4599 trial
- Bevacizumab with chemotherapy: overall survival
- Outcomes for elderly advanced NSCLC
- Economic analysis: all else being equal...
- Quality of life and symptom control
- Cisplatin+pemetrexed vs. cisplatin+gemcitabine
- Overall survival
- Overall survival in non-squamous patients
- Why phase III trials? (3)
- ECOG 4599 trial - advanced NSCLC
- INT SCLC study of daily vs. BID radiotherapy
- The future of phase III trials
- The importance of phase II studies
- Targeted populations
- FLEX: 1st-line stage IIIB/IV NSCLC
- N0723: predictive marker study design
- An opportunity to utilize improved prognosis
- How to use phase III data
- JCOG trial: CDDP/CPT-11 vs. CDDP/VP-16
- Overall survival in the U.S.A
- Summary and conclusions
Topics Covered
- Phase III trials: definition and difficulties
- Statistical aspects: planning, execution and analysis
- Why phase III trials?
- Phase II results are not always correct
- Unsuspected risks and benefits may be revealed
- Economic analysis
- The future of phase III trials
- Targeted therapies and targeted populations
- How to use phase III results
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Edelman, M. (2009, January 6). Phase III trials [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2019, from https://hstalks.com/bs/1116/.Publication History
Financial Disclosures
- Prof. Martin Edelman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Phase III trials
Published on January 6, 2009
32 min